As Lilly Deals with Yet Another Set-Back in Entering the US Rheumatoid Arthritis Market, Pfizer's Xeljanz Further Solidifies Its Position as a Go-To Alternate Mechanism of Action Agent, According to a Recently Published Study by Spherix Global Insig

EXTON, Pa., Feb. 20, 2018 /PRNewswire/ -- Since receiving a Complete Response Letter from the FDA for their Incyte partnered investigational JAK 1/2 inhibitor, baricitinib (Olumiant), Eli Lilly's entrance into the rheumatoid arthritis (RA) market has been met with challenge.  Most recently...